Solosec® (secnidazole)
Bacterial vaginosis and trichomoniasis
ApprovedCommercial (Acquired)
Key Facts
Indication
Bacterial vaginosis and trichomoniasis
Phase
Approved
Status
Commercial (Acquired)
Company
About Evofem Biosciences
Evofem Biosciences is dedicated to addressing critical unmet needs in women's healthcare through innovative, hormone-free products. The company successfully launched Phexxi®, a first-in-class vaginal pH modulator for on-demand contraception, and acquired Solosec®, a single-dose oral antibiotic for bacterial vaginosis. With a growing commercial footprint and a pipeline exploring new indications, Evofem is targeting a multi-billion dollar market opportunity in contraception and sexual health.
View full company profile